Concurrent Investment Advisors LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 77.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,565 shares of the medical equipment provider’s stock after purchasing an additional 24,166 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Boston Scientific were worth $2,371,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Renaissance Group LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $28,064,000. Perigon Wealth Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd raised its position in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in Boston Scientific during the 2nd quarter worth $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Boston Scientific by 9.9% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.
Boston Scientific Stock Down 5.9% Boston Scientific stock opened at $45.00 on Wednesday. The stock’s 50 day moving average price is $47.04 and its 200 day moving average price is $55.18. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a market cap of $65.22 billion, a PE ratio of 18.22, a price-to-earnings-growth ratio of 1.10 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year. Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.
Key Stories Impacting Boston Scientific Here are the key news stories impacting Boston Scientific this week:
Positive Sentiment: Boston Scientific said manufacturing and shipping operations are recovering, which could limit the disruption and support a gradual rebound in revenue and profitability. The company also expects multiple product launches and cost savings to aid longer-term growth. Boston Scientific Says It Won’t Meet 2026 Guidance After Cyberattack Neutral Sentiment: The company has not provided a replacement forecast, leaving investors without clear visibility into the size or duration of the financial impact. Management’s ability to restore systems and normalize shipments will be key near-term catalysts. Boston Scientific says cyberattack likely to hurt 2026 sales, profit Negative Sentiment: Boston Scientific said it is unlikely to meet its 2026 net-sales growth and earnings-per-share guidance ranges, including its previously issued third-quarter and full-year outlook. That reversal is driving the stock’s decline because it signals weaker near-term revenue, profit and cash-flow expectations. Boston Scientific Won’t Meet Guidance Due to Cyberattack Negative Sentiment: The incident adds operational and execution risk to pressure already affecting parts of the portfolio, including WATCHMAN and electrophysiology products. Investors are now likely to focus on the timing of the recovery, the ultimate size of the earnings shortfall and whether customer orders can be fully restored. Boston Scientific’s 2026 Growth Outlook Weakens Insider Activity In other news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig purchased 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.
Analyst Ratings Changes Several equities research analysts have recently weighed in on the stock. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Weiss Ratings cut Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Citigroup decreased their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Needham & Company LLC dropped their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $71.62.
Read Our Latest Stock Report on BSX
Boston Scientific Company Profile (Free Report)
Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.
The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.
Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.
Read More Five stocks we like better than Boston Scientific Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
Boston Scientific (BSX.N) said on Tuesday it no longer expects to meet its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts, after a cybersecurity incident disrupted the medical device maker's global operations.
An unauthorized activity on some of its information technology systems, first identified on August 25, caused a network outage that disrupted manufacturing and the processing and shipment of customer orders, the company said in a regulatory filing.
Stifel analyst Rick Wise said investors increasingly view 2026 as a "lost year" for Boston Scientific and are likely to focus more on the company's prospects for 2027.
Shares of the company were down 2.3% in morning trading.
In July, Boston Scientific had forecast 2026 adjusted earnings of $3.28 to $3.32 per share and sales growth of 5.5% to 6.5% on a reported basis. For the third quarter, it had projected adjusted earnings of 80 cents to 82 cents per share.
It expects to recover a portion of the affected revenue as it ramps up operations and works through backlogs, but said the full financial impact remains uncertain.
The incident is the latest in a series of cyberattacks on the healthcare sector, with medical device makers Abbott Laboratories (ABT.N), Stryker (SYK.N) and Medtronic (MDT.N) and drugmaker Novo Nordisk (NOVOb.CO) among those recently hit.
In an update on Saturday, Boston Scientific said that the incident's effects were limited to select internal infrastructure and that product quality analyses found no impairment beyond disruptions to new activations of its cardiac device remote-monitoring platform.
J.P.Morgan analyst Robbie Marcus said the cyberattack clouds visibility into Boston Scientific's underlying business trends, delaying investors' ability to assess growth and competitive dynamics in key franchises, including electrophysiology and heart device Watchman.
The company said major distribution centers are now processing and shipping orders at or above normal levels, sterilization facilities are operational, and manufacturing has resumed across most facilities globally.
Boston Scientific plans to provide an updated outlook when it reports third-quarter results on October 28.
Boston Scientific said it likely won't meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Key Takeaways Boston Scientific cut 2026 growth expectations as WATCHMAN and EP face mounting U.S. pressure.Boston Scientific expects 2027 growth to stay muted before new catalysts could lift results in 2028.Boston Scientific lost 55.8% over 12 months, while its 14.13 forward P/E trails historical and industry norms. Boston Scientific (BSX - Free Report) has entered the second half of 2026 with more pressure than expected as weakness in two important businesses weighs on its near-term performance. WATCHMAN has been hurt by a sharp slowdown in the U.S. market, with clinical evidence affecting referral patterns. In Electrophysiology (“EP”), the company is facing greater competitive share losses in the United States than expected. Together, these headwinds are making it more challenging for the company to deliver the growth it has historically achieved.
Boston Scientific lowered its 2026 expectations, now calling for organic revenue growth of 5% to 6% and adjusted earnings per share (EPS) of $3.28 to $3.32, or 7% to 8% growth. Management expects the pressure to extend into 2027, when revenue growth could remain below its weighted average market growth rate and adjusted EPS growth may be limited.
On a positive note, growth could pick up meaningfully in 2028, as new catalysts begin to take effect. Based on investments made over the past two or three years, the company will have seven new launches that surpass nearly $25 billion in total addressable market (TAM). Among them are the planned launch of the SEISMIQ 4CE Coronary IVL Catheter in the first half of 2027 after positive FRACTURE trial data and the introduction of the FARAWAVE Ultra mapping and ablation catheter. The pending Penumbra acquisition could also strengthen Boston Scientific’s long-term growth profile.
The company is pursuing a restructuring program targeting approximately $500 million in annual run-rate savings by the end of 2029, with more than half expected by the end of 2027. The savings will be focused in the areas of supply-chain optimization, targeted functional changes, organizational restructuring and reductions in indirect spending, supporting operating-margin expansion and stronger adjusted EPS growth in 2028 and beyond.
Latest Developments Among BSX’s PeersAbbott (ABT - Free Report) recently presented new late-breaking 12-month data from the FlexPulse Global IDE study, showing favorable safety and effectiveness outcomes for the company’s investigational TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with challenging cases of atrial fibrillation. Abbott’s Nutrition business also launched Similac 360 Total Care Made With Whole Milk, the only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States.
Globus Medical’s (GMED - Free Report) Excelsius3D intelligent 3-in-1 imaging system achieved the CE mark for commercial sale in the European Union and the United Kingdom. The system received FDA’s 510(k) clearance in 2021. The addition of Excelsius3D expands the company’s Excelsius Ecosystem of enabling technologies and enhances the capabilities of the ExcelsiusGPS robotic navigation system in the European Union. Globus Medical also announced the acquisition of Higgs Boson Health, a Duke University-incubated digital healthcare company based in Durham, NC.
BSX’s Price Performance, Valuation and EstimatesOver the past 12 months, Boston Scientific shares have plunged 55.8% compared with the industry’s 27.1% decline.
Image Source: Zacks Investment Research
Boston Scientific trades at a forward earnings multiple of 14.13 over the past 12 months, lower than its historical median and industry average.
Image Source: Zacks Investment Research
The company’s earnings estimates have trended lower over the past three months.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific Corporation (NYSE:BSX) anticipates a material hit to its third-quarter and full-year 2026 financial results following an August cybersecurity incident that disrupted global operations.
The company expects to miss its previously issued net sales and earnings guidance as a result.
Operational Disruptions And Recovery EffortsThe unauthorized activity on certain company systems, detected on Aug. 25, triggered a network outage affecting access to operating systems and business applications.
These system failures hampered the company’s ability to manufacture, process, and ship customer orders.
In response, leadership activated containment protocols and enlisted third-party cybersecurity professionals to investigate the breach.
The company said it has not identified evidence of ongoing unauthorized access to its systems, though the investigation remains ongoing. Boston Scientific has not disclosed whether any data was compromised.
Major distribution centers are now processing and shipping customer orders at or above normal operating levels.
Furthermore, sterilization facilities and most global manufacturing plants are operational again, although a timeline for complete system restoration remains unknown.
Read Next
Financial Outlook And Future UpdatesBecause of the outage, the firm believes it will fall short of the adjusted earnings per share and net sales growth projections issued in late July.
On July 29, the medical device maker guided third-quarter net sales growth of approximately 3%-5% on a reported and organic basis, equivalent to sales of $5.217 billion-$5.318 billion, versus a consensus of $5.358 billion. It had also guided to adjusted earnings of 80-82 cents, against a consensus of 83 cents.
The company now says it is unlikely to reach either range.
While management expects to recoup a portion of the delayed revenue by clearing backlogs and fulfilling pending orders, the complete financial fallout remains unclear.
Executives plan to detail the revised financial and operational outlook during the third-quarter earnings conference call scheduled for Wednesday, Oct. 28.
Despite the near-term headwinds, the company does not foresee the cyberattack causing long-term material damage to its overall financial condition.
BSX Stock Price Activity: Boston Scientific shares were down 5.31% at $45.26 on Tuesday, according to Benzinga Pro data.
AlphaGrep UK Ltd acquired a new position in shares of Boston Scientific Corporation (NYSE: BSX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,906 shares of the medical equipment provider's stock, valued at approximately $978,000. Other large investors
Boston Scientific (BSX - Free Report) closed the most recent trading day at $46.95, moving -2.94% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.06%. At the same time, the Dow added 1.18%, and the tech-heavy Nasdaq gained 1.4%.
Shares of the medical device manufacturer witnessed a gain of 1.32% over the previous month, trailing the performance of the Medical sector with its gain of 5.75%, and the S&P 500's gain of 2.46%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is predicted to post an EPS of $0.8, indicating a 6.67% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $5.28 billion, up 4.22% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.3 per share and revenue of $21.33 billion, indicating changes of +7.84% and +6.28%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Boston Scientific is currently a Zacks Rank #4 (Sell).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 14.65. This indicates a discount in contrast to its industry's Forward P/E of 21.
It is also worth noting that BSX currently has a PEG ratio of 1.12. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Products industry stood at 1.88 at the close of the market yesterday.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 93, placing it within the top 38% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Key Takeaways BSX faces an uncertain cyberattack impact amid disruptions to manufacturing and customer order processing.BSX lowered 2026 guidance as WATCHMAN and Electrophysiology face unexpected headwinds.BSX has plunged 49.1% YTD, trades below key SMAs and carries a premium to its industry. Boston Scientific (BSX - Free Report) , the Marlborough-based medical device maker, is navigating a challenging period. On Aug. 25, the company disclosed a cybersecurity incident that affected access to certain operating systems and business applications, including its ability to manufacture products, as well as process and ship customer orders.
Once detected, Boston Scientific activated its incident response protocols and launched an investigation with the help of CrowdStrike and other third-party experts. The company is working to restore affected operations, but the timeline for full recovery and the financial impact remain uncertain. The incident also comes amid a series of recent cybersecurity incidents across the medical device industry. BSX’s peer Abbott (ABT - Free Report) faced a cyber incident in July that impacted a limited number of internal systems in its Cancer Diagnostics business, while Medtronic (MDT - Free Report) faced a cyber issue in April that impacted a few of its corporate IT systems.
Adding to the pressure, the latest development comes on top of a weaker annual outlook issued during the second-quarter earnings call in late July. Despite beating top- and bottom-line estimates, Boston Scientific lowered its full-year 2026 organic sales guidance to 5-6% and adjusted earnings per share (EPS) guidance to $3.28-$3.32. Foreign exchange is expected to create a roughly $0.05 headwind to the bottom line. Full-year adjusted gross margin is also projected to fall from the 2025 levels, largely due to unexpected headwinds within two high-growth franchises, WATCHMAN and Electrophysiology (“EP”).
BSX Stock Price PerformanceYear to date, shares of Boston Scientific have plunged 49.1% compared with its industry’s 17% decline and the Medical sector’s 4.2% growth. The S&P 500 composite has risen 10.8% during the period. BSX has also significantly trailed both Abbott and Medtronic, whose shares have dropped 11.8% and 4%, respectively, during the same period.
Image Source: Zacks Investment Research
BSX’s Technical IndicatorsThe following chart also shows that BSX is currently trading below its 90- and 200-day simple moving averages (SMAs), pointing to continued bearish momentum.
Image Source: Zacks Investment Research
Factors Impacting Boston ScientificSluggish Recovery in Urology: The Urology business within the company’s MedSurg segment fell short of internal expectations, growing just 1% in the second quarter of 2026. The weakness stemmed from underperformance in the stone management franchise due to volume-based procurement in China, and some key product gaps in the core stone portfolio. Sacral neuromodulation also continued to see the impact of commercial model disruption. Management now expects full-year Urology growth to be flat to low-single digits.
CRM’s Portfolio Gaps: Boston Scientific’s Cardiac Rhythm Management (“CRM”) continued to face pressure, with sales down 2% in the second quarter. The core business saw a high-single-digit decline in low-voltage products and a mid-single-digit decline in high-voltage products. Competitive pressures and gaps in the company’s portfolio are adding to these challenges. Management expects growth in this division to be flat for 2026, with only modest improvement later in the year, supported by the full launch of EluPro.
WATCHMAN Demand Weakness: WATCHMAN’s U.S. market has slowed sharply and unexpectedly because of compounding clinical evidence regarding stroke risk in AF patients affecting referral patterns. The rapid uptake of concomitant procedures has also created operational inefficiencies, making it difficult to sustain growth. Against this backdrop, Boston Scientific now expects global WATCHMAN growth to be flat to low-single digits in 2026, with the second-half growth declining mid- to high-single digits on a year-over-year basis. Third-quarter U.S. sales are projected to decline sequentially, while concomitant growth is also expected to slow materially in the second half due to tougher comparisons with 2025.
Rising Competition Hits Electrophysiology: Boston Scientific is facing an unanticipated degree of competitive share movement in the U.S. EP market. The rapid adoption of the FARAPULSE technology has pushed U.S. pulsed field ablation revenues to approximately 80% of the atrial fibrillation market. With this faster-than-anticipated penetration, the company’s ability to offset some competitive pressures has become limited. Management has adjusted its market share assumptions to reflect these developments and now expects global Electrophysiology growth to be flat in the second half of 2026. U.S. sales in the third quarter are expected to decline in the mid-single digits sequentially.
As shown below, estimates for BSX’s 2026 and 2027 earnings have been steadily revised downward.
Image Source: Zacks Investment Research
BSX’s ValuationBoston Scientific currently trades at a forward price/sale (P/S) of 3.17X over the past 12 months, below its median of 4.77X but above the industry average of 2.23X. The stock sits with a Value Score of C.
Image Source: Zacks Investment Research
EndnoteBoston Scientific is yet to fully assess the financial consequences of the cybersecurity incident, if any, that has disrupted its global operations. The company is also dealing with several other challenges across its businesses, including weaker U.S. demand in WATCHMAN and portfolio gaps within CRM. The lowered full-year 2026 financial outlook further reflects these pressures. So far this year, BSX has been a major underperformer compared to its benchmarks and key peers. Although trading below its historical median, the stock still carries a premium to the industry. The company’s earnings outlook has also continued to slide in recent months. Given all these factors, current BSX holders should consider exiting their positions.
Boston Scientific carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
B. Metzler seel. Sohn & Co. AG boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 25.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 333,583 shares of the medical equipment provider’s stock after acquiring an additional 68,450 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Boston Scientific were worth $14,237,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter worth about $26,000. Sfam LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth about $29,000. Finally, Cresta Advisors Ltd. acquired a new position in shares of Boston Scientific during the 4th quarter valued at about $33,000. 89.07% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In BSX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Oppenheimer reduced their target price on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday, July 27th. Jefferies Financial Group decreased their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Finally, TD Cowen reiterated a “buy” rating and set a $56.00 price objective on shares of Boston Scientific in a research note on Tuesday, August 25th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.
Read Our Latest Stock Analysis on Boston Scientific Boston Scientific Stock Performance Shares of BSX stock opened at $48.40 on Thursday. The company’s 50 day moving average price is $46.77 and its two-hundred day moving average price is $55.99. The company has a market capitalization of $70.14 billion, a P/E ratio of 19.59, a price-to-earnings-growth ratio of 1.11 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50.
Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.
Boston Scientific declared that its Board of Directors has authorized a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
Insider Activity In related news, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger bought 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.
(Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Recommended Stories Five stocks we like better than Boston Scientific Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
Boston Scientific (BSX.N) said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.
The medical device maker said it detected the incident on August 25 and had activated incident-response procedures, working with third-party cybersecurity specialists to investigate and contain the threat.
Shares of the company fell about 4% in morning trading.
The incident is the latest in a series of cyberattacks to hit the healthcare sector, with medical device makers Abbott Laboratories (ABT.N), Stryker (SYK.N) and Medtronic (MDT.N), health insurer Clover Health (CLOV.O), drugmaker Novo Nordisk (NOVOb.CO) and drug-delivery equipment supplier West Pharmaceutical Services (WST.N) among those recently hit.
The attack is expected to continue affecting parts of the company's business while recovery efforts are underway, Boston Scientific said.
Evercore ISI analyst Vijay Kumar said Stryker's cybersecurity incident earlier this year took about three weeks to resolve and assuming a similar recovery timeline, Boston Scientific could face a roughly 600 to 700 basis-point impact on third-quarter revenue.
Boston Scientific said it has not determined whether the incident was reasonably likely to have a material impact on its business.
An investigation is ongoing, but the full scope and nature of the incident have not yet been determined, the company said.
Boston Scientific said Wednesday it was hit with a cyberattack this week that is affecting its operations. The disclosure sent shares of the $72 billion medical device maker lower.
The attack is disrupting Boston Scientific's access to company information systems and applications, including shipments services, it said in a Securities and Exchange Commission filing.
"While the company is working diligently to restore affected functions and systems access, the timeline for a full restoration is not yet known," the filing said.
Boston Scientific's stock was down 4.5% in morning trading Wednesday. Shares of the maker of devices such as pacemakers and stents have been nearly cut in half already this year, under pressure after issuing a weak profit forecast in the first quarter.
When asked to comment, the company reiterated the info from the SEC filing.
Analysts at investment bank Piper Sandler said that they spoke to company management on Wednesday morning and that they thought it may be weeks before Boston Scientific can resume normal business operations.
"We believe BSX may be able to return to shipping all of its products in less than three weeks," Matt O'Brien at Piper Sandler wrote.
"The company is unable to process and ship orders, so sales will likely be adversely impacted," he wrote, adding that "clearly, this is not great for a company that is already seeing sales growth slow."
Boston Scientific (BSX +0.36%) stock turned sharply lower today, falling as much as 5.9%. As of 1:00 p.m. ET, the stock was still down 3.5%.
The catalyst that sent the medical device maker lower was news that the company had been hacked.
Image source: Getty Images.
Business disruption In a regulatory filing submitted late Tuesday, Boston Scientific revealed that it had "identified a cybersecurity incident" affecting some of its information technology (IT) systems, resulting in a "global disruption" to its operations. The filing went on to say that the company had "activated its incident response protocols" and that the issue was impacting its "ability to process and ship customer orders." Boston Scientific also admitted that the investigation was ongoing and that the full scope of the incident and its operational and financial impacts weren't yet known.
Premium Feature
Moneyball Superscore
77/100
Today's Change
(
0.36
%) $
0.17
Current Price
$
46.84
Cybersecurity incidents, data breaches, and ransomware attacks are becoming all too common, and advances in artificial intelligence (AI) are only making matters worse. In its 2026 "Cost of a Data Breach" report, IBM revealed that the global average cost of a data breach rose to $5 million. Losses are not limited to the detection and remediation of the incident but also include lost business. The average cost of a breach in the U.S. is even higher, climbing to a record $11.5 million, more than twice the global average and up 13% compared to last year.
Perhaps the biggest problem with security breaches is the loss of confidence among customers and users, which can cause some to move on.
Only time will tell how serious this cybersecurity incident was for Boston Scientific. Investors should keep a weather eye on the horizon as new details emerge.
Danny Vena, CPA, has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends International Business Machines. The Motley Fool has a disclosure policy.
On Tuesday, Boston Scientific Corporation (NYSE:BSX) identified a cybersecurity incident on Tuesday that caused global operational disruptions, including delays in processing and shipping customer orders.
The company activated its incident response plan and hired third-party cybersecurity experts to contain the threat. In a Wednesday SEC filing, the medical device maker noted that system access remains limited and the timeline for full restoration is currently unknown.
Boston Scientific Says Scope And Financial Impact Remain UnclearThe company’s investigation of the cybersecurity incident is ongoing, and the full scope, nature, and impacts, including operational and financial impacts, of the incident are not yet known.
Accordingly, the company has not yet determined whether the incident is reasonably likely to have a material impact on the company.
Read Next
Boston Scientific cut its fiscal 2026 outlook, citing pressures on the Watchman and EP markets.
The medical technology giant reported revenues of $5.442 billion on Wednesday, better than the consensus estimate of $5.361 billion, beating the management guidance of $5.34 billion-$5.44 billion.
In June, Novo Nordisk A/S (NYSE:NVO) said it is investigating claims by cyber extortion group FulcrumSec, which alleges it stole more than a terabyte of data from the pharmaceutical company and is considering selling portions of the information after an unsuccessful $25 million ransom demand.
BSX Stock Price Activity: Boston Scientific shares were down 4.32% at $47.70 at the time of publication on Wednesday, according to Benzinga Pro data.
Read Next
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
A cyberattack on U.S. medical device maker Boston Scientific is causing an ongoing “global disruption” to its operations, according to a federal regulatory filing on Wednesday. This is the latest health tech giant to face a cyberattack in recent weeks.
The Massachusetts-based company, which makes medically implanted devices like pacemakers and defibrillators, confirmed in a filing with the U.S. Securities and Exchange Commission that on Tuesday it began experiencing “disruptions and limitations of access” to its IT systems and business applications critical for its operations.
Boston Scientific said the cyberattack has affected its ability to ship and process orders, but has not said whether the disruption extends to customers with medical devices and implants.
When asked by TechCrunch, Boston Scientific spokesperson Chanel Hastings shared the company’s public statement but would not comment on whether patients are affected by the cyberattack, say what steps patients should take, or answer questions about the nature of the incident.
Boston Scientific treats around 48 million patients a year, according to its website.
The company’s public statement said that its investigation is ongoing and that a timeline for its restoring its systems is not yet known.
It’s not clear what caused the cyberattack at Boston Scientific. Local media in Ireland reported that thousands of staff across Boston Scientific’s campus in Cork were sent home on Tuesday after network communications were cut across the company.
Boston Scientific is the latest health technology company to have been hacked this year, including medical device makers Abbott Laboratories and Medtronic. Earlier this year, Iranian-backed hackers were blamed for a cyberattack on U.S. medical device maker Stryker, which allowed the hackers to remotely wipe tens of thousands of employee devices across its Windows network by abusing a centralized device management portal provided by Microsoft.
According to public internet records, Boston Scientific relies largely on Microsoft and Amazon Web Services for its corporate infrastructure.
Do you know more about Boston Scientific’s cyberattack? Do you work at Boston Scientific or have you received communications from the company or the hackers? Contact this reporter via encrypted message at zackwhittaker.1337 on Signal.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
Zack Whittaker is the security editor at TechCrunch. He also authors the weekly cybersecurity newsletter, this week in security.
He can be reached via encrypted message at zackwhittaker.1337 on Signal. You can also contact him by email, or to verify outreach, at [email protected].
Boston Scientific (BSX +0.36%), a global medical device maker, closed at $48.17, down 3.38%. Premarket reports said a cybersecurity incident disrupted global operations and shipping. The company also announced a product recall for certain types of its percutaneous catheters, further weighing on the stock. Investors are watching how quickly the company restores its systems and whether the recall exacerbates the interruption. Trading volume reached 31.8M shares, coming in about 48% above its three-month average of 21.4M shares.
How the markets moved todayS&P 500 (^GSPC -0.25%) fell 0.04% to 7,675, and the Nasdaq Composite (^IXIC -0.52%) slipped 0.08% to 26,130. Among medical devices and interventional medtech peers, Abbott Laboratories (ABT +0.79%) closed at $114.10, down 1.75%, while Medtronic (MDT +1.40%) finished at $92.01, up 0.95%, as Boston Scientific's cyber disruption stood out.
What this means for investorsBoston Scientific has seen its stock drop 55% over the last year, and today's double dose of bad news didn't help things. The product recall is tied to the company's ENROUTE Transcarotid Neuroprotection System (NPS) following the FDA's concerns about the potential separation of the product's arterial sheath tip.
Making matters worse, the company also disclosed a cybersecurity incident that disrupted its global operations, potentially disrupting the processing and shipping of customers' orders. Management noted that it was working to restore lost functions but couldn't yet determine whether the event would have a material impact on BSX shares.
Following several quarters of weaker-than-expected earnings results, disappointing Watchman sales, slashed guidance, and a major acquisition now weighing on Boston Scientific's balance sheet, the stock has shifted from a steady compounder to more of a turnaround or value type of stock -- especially after today's news. While BSX stock is on my watch list, I'd need to see some type of positive developments before I consider buying.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Medtronic. The Motley Fool has a disclosure policy.
It has been about a month since the last earnings report for Boston Scientific (BSX - Free Report) . Shares have added about 1.5% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
BSX Q2 Earnings and Revenues Top EstimatesBoston Scientific reported second-quarter 2026 adjusted earnings of 86 cents per share, up 14.7% year over year. The figure beat the Zacks Consensus Estimate by 3.6%.
Revenues rose 7.5% on a reported basis to $5.44 billion and surpassed the consensus estimate by 1.1%. Cardiovascular growth, double-digit gains in Asia-Pacific (APAC) and Latin America and Canada (LACA) and strong Neuromodulation sales supported the quarter.
Segmental Results Reflect Broad-Based GrowthCardiovascular revenues totaled $3.62 billion, increasing 8.3% on a reported basis and 7.8% on an operational and organic basis. The segment generated roughly two-thirds of Boston Scientific’s quarterly revenues and remained the primary growth contributor.
MedSurg revenues rose 5.9% to $1.82 billion, with operational and organic growth of 5.4%. Within the segment, Endoscopy sales increased 7.6% to $793 million, while Neuromodulation revenues climbed 12.7% to $341 million. Urology revenues advanced 1.1% to $684 million, marking the slowest growth among the company’s reported businesses.
Broad Regional Sales GainsU.S. revenues increased 6.2% to $3.43 billion. The domestic market remained Boston Scientific’s largest region, generating nearly 63% of consolidated sales.
APAC revenues rose 11.2% to $878 million, while LACA sales surged 22.4% to $206 million. LACA operational growth was 16.2%. Europe, Middle East and Africa (“EMEA”) revenues increased 6.1% to $932 million, although operational growth was lower at 4.2% due to currency effects.
Boston Scientific Expands Quarterly MarginsThe gross margin expanded approximately 306 basis points (bps) year over year to 70.7%. The cost of products sold declined 2.6% to $1.59 billion in the reported quarter.
Selling, general and administrative expenses rose 5.1% to $1.80 billion. Research and development expenses increased 5.3% to $554 million, while royalty expenses plunged 14.3% to $12 million. Adjusted operating margin expanded approximately 71 bps to 28.4%.
BSX Advances Its Cardiovascular PipelineBoston Scientific presented data from the FRACTURE trial of the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The study met its primary endpoints, demonstrating procedural success and high freedom from major adverse cardiac events at 30 days.
The AVANT GUARD study also met its safety and effectiveness endpoints. FARAPULSE pulsed field ablation demonstrated statistical superiority over anti-arrhythmic drugs in patients with persistent atrial fibrillation who had not received prior treatment for the condition.
New Growth InvestmentsThe company invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire its transcatheter aortic valve replacement business. MiRus is developing the investigational SIEGEL balloon-expandable TAVR system.
BSX also completed its previously announced $2 billion accelerated share repurchase program. The transaction resulted in the repurchase of approximately 40 million shares, reducing the company’s outstanding share base.
Q3 and Full-Year GuidanceBoston Scientific now expects reported sales growth of 5.5-6.5%, down from its prior forecast of 7-8.5%. Organic sales growth is now projected at 5-6% compared with the earlier range of 6.5-8%.
The company also reduced its full-year adjusted earnings forecast to $3.28-$3.32 per share from the earlier $3.34-$3.41.
For the third quarter, management forecasts reported and organic sales growth of 3-5%. Adjusted earnings are expected between 80 cents and 82 cents per share.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.
VGM ScoresCurrently, Boston Scientific has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock has a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Boston Scientific has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry PlayerBoston Scientific belongs to the Zacks Medical - Products industry. Another stock from the same industry, Royal Philips (PHG - Free Report) , has gained 1.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Philips reported revenues of $5.07 billion in the last reported quarter, representing a year-over-year change of +3%. EPS of $0.57 for the same period compares with $0.41 a year ago.
Philips is expected to post break-even earnings per share for the current quarter, representing a year-over-year change of 0%. Over the last 30 days, the Zacks Consensus Estimate has changed 0%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Philips. Also, the stock has a VGM Score of A.
Callan Family Office LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 52,745 shares of the medical equipment provider’s stock, valued at approximately $2,251,000.
Other large investors also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Boston Scientific in the second quarter worth approximately $5,534,781,000. Norges Bank acquired a new stake in shares of Boston Scientific in the 4th quarter valued at $2,199,395,000. Bank of New York Mellon Corp bought a new stake in Boston Scientific in the second quarter worth $339,031,000. Deutsche Bank AG acquired a new position in Boston Scientific during the second quarter worth $254,247,000. Finally, Assenagon Asset Management S.A. increased its position in Boston Scientific by 133.6% during the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after buying an additional 5,751,760 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.
Insiders Place Their Bets In other news, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth A number of analysts have weighed in on BSX shares. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a research report on Wednesday, July 29th. Oppenheimer lowered their price objective on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 27th. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Argus restated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Finally, TD Cowen decreased their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $71.62. Get Our Latest Research Report on BSX
Boston Scientific Stock Up 2.1% Shares of NYSE BSX opened at $50.39 on Friday. The stock has a market cap of $73.03 billion, a PE ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56. The business has a fifty day moving average of $46.34 and a two-hundred day moving average of $57.86. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.
Boston Scientific announced that its Board of Directors has authorized a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.
(Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles Five stocks we like better than Boston Scientific 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
Asahi Life Asset Management CO. LTD. bought a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,155 shares of the medical equipment provider’s stock, valued at approximately $433,000.
A number of other institutional investors have also recently made changes to their positions in BSX. Kelleher Financial Advisors purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $25,000. FWL Investment Management LLC purchased a new position in Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. bought a new position in Boston Scientific in the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the 4th quarter worth about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific in the 1st quarter worth about $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Insider Activity at Boston Scientific
In other news, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders bought 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.
Boston Scientific Stock Up 3.1%
Shares of BSX stock opened at $52.02 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company’s fifty day moving average price is $46.22 and its 200-day moving average price is $58.22. The company has a market capitalization of $75.39 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.10 and a beta of 0.56.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.
Boston Scientific announced that its Board of Directors has authorized a stock buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
Analyst Upgrades and Downgrades
BSX has been the subject of a number of research reports. TD Cowen decreased their price target on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Mizuho lowered their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $60.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Truist Financial cut their price target on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $71.62.
Read Our Latest Report on BSX
Boston Scientific Company Profile
(Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Stories
Five stocks we like better than Boston Scientific
Bloom Energy’s AI Surge Meets a Valuation Reality Check
Target Is Winning Shoppers Back—Can the Rally Reach $180?
IonQ’s Space Contract Points to a New Frontier for Quantum Investors
Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
Aurora Investment Counsel bought a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 43,857 shares of the medical equipment provider’s stock, valued at approximately $1,872,000.
A number of other institutional investors have also recently made changes to their positions in BSX. Kelleher Financial Advisors bought a new position in Boston Scientific in the 2nd quarter valued at approximately $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific during the first quarter valued at $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Insider Buying and Selling at Boston Scientific In related news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 194,522 shares of company stock valued at $9,385,210 in the last three months. Company insiders own 0.34% of the company’s stock.
Boston Scientific Trading Up 3.1% BSX stock opened at $52.02 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The business has a 50 day simple moving average of $46.22 and a two-hundred day simple moving average of $58.22. The company has a market capitalization of $75.39 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.10 and a beta of 0.56. Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the business posted $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.
Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
Analyst Upgrades and Downgrades BSX has been the topic of a number of recent analyst reports. Needham & Company LLC dropped their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Oppenheimer lowered their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday, July 27th. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Finally, Raymond James Financial reissued an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.
Get Our Latest Research Report on Boston Scientific
(Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles Five stocks we like better than Boston Scientific Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
Boston Scientific has corrected sharply due to EP and WATCHMAN slowdowns, but 74% of its portfolio continues healthy growth. Weakness in BSX's EP business appears addressable with new product launches like FARAWAVE Ultra and ICE, expected to drive recovery from 2H 2027 onward. Valuation is compelling: BSX trades at 15.27x forward earnings, a significant discount to peers and historical averages, despite resilient core businesses.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Boston Scientific currently has an average brokerage recommendation (ABR) of 1.53, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 30 brokerage firms. An ABR of 1.53 approximates between Strong Buy and Buy.
Of the 30 recommendations that derive the current ABR, 21 are Strong Buy and four are Buy. Strong Buy and Buy respectively account for 70% and 13.3% of all recommendations.
Brokerage Recommendation Trends for BSX
Check price target & stock forecast for Boston Scientific here>>>
The ABR suggests buying Boston Scientific, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Should You Invest in BSX?Looking at the earnings estimate revisions for Boston Scientific, the Zacks Consensus Estimate for the current year has declined 1.8% over the past month to $3.3.
Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for Boston Scientific. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, it could be wise to take the Buy-equivalent ABR for Boston Scientific with a grain of salt.
B. Riley Wealth Advisors Inc. reduced its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 56.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 8,467 shares of the medical equipment provider’s stock after selling 10,822 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Boston Scientific were worth $368,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of BSX. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific during the fourth quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd purchased a new stake in Boston Scientific during the first quarter worth about $28,000. Finally, Sfam LLC purchased a new stake in Boston Scientific during the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Insider Activity at Boston Scientific In related news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig purchased 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 204,322 shares of company stock valued at $9,939,221 over the last 90 days. Company insiders own 0.34% of the company’s stock.
Wall Street Analysts Forecast Growth BSX has been the topic of a number of recent research reports. BTIG Research cut their price objective on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 29th. Oppenheimer decreased their target price on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 27th. Needham & Company LLC lowered their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, July 8th. Canaccord Genuity Group cut their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.
View Our Latest Analysis on BSX
Boston Scientific Price Performance BSX stock opened at $51.40 on Thursday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $74.49 billion, a P/E ratio of 20.81, a PEG ratio of 1.12 and a beta of 0.56. The business has a 50 day simple moving average of $45.94 and a 200-day simple moving average of $59.69. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the company earned $0.75 earnings per share. The business’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.
Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
Boston Scientific Company Profile (Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Recommended Stories Five stocks we like better than Boston Scientific GE Vernova’s AI Power Boom Faces a Profit Test Cardinal Health Earnings: Can Perfection Get Priced In Twice? Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Legacy Jet Builders Stall While Embraer Accelerates to New Highs Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBallast Inc. Has $6.41 Million Stock Holdings in Johnson & Johnson $JNJ
NEXT HEADLINE »Ballast Inc. Grows Position in Vanguard Extended Market ETF $VXF
E. Ohman J or Asset Management AB cut its holdings in Boston Scientific Corporation (NYSE: BSX) by 91.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,275 shares of the medical equipment provider's stock after selling 541,890 shares during the
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (BSX +2.48%), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing.
Today's Change
(
2.48
%) $
1.23
Current Price
$
50.54
Transaction summaryMetricValueTransaction value$10.1 millionShares purchased208,359Post-transaction shares (total)1,612,143Post-transaction shares (directly held)1,590,024Post-transaction shares (indirectly held)22,119Post-transaction value$78.08 millionTransaction value based on SEC Form 4 weighted average purchase price ($48.34); post-transaction value based on August 03, 2026 market close ($48.43).
Key questionsHow significant is this acquisition relative to the CEO's existing position?
The purchase of ~208,000 shares represents a 13% expansion of Michael F. Mahoney's total equity interest. Following the transaction, he maintains a combined position of ~1.6 million shares valued at approximately $78.08 million based on the Aug. 3, 2026 market close.What was the execution context for this $9.0 million trade?
The acquisition was completed through multiple trades at prices ranging from $47.87 to $48.47 per share. According to filing footnotes, most of the transaction was a direct purchase by the executive, with about 22,000 shares bought as a discretionary rebalancing of holdings within the company’s 401(k) Retirement Savings Plan.How does this purchase align with recent stock performance?
The transaction was executed following a period of negative price momentum, as Boston Scientific recorded a -54% return over the 12 months ending on the transaction date. As of the Aug. 4, 2026 market close, the stock was priced at $49.09, slightly above the CEO’s weighted-average entry price of $48.34.What is the current structure of the CEO's beneficial ownership?
The majority of the CEO's holdings are held directly, totaling 1,590,024 shares. In addition to the 22,119 shares held indirectly through a 401(k) plan, Michael F. Mahoney also holds derivative securities in the form of stock options and awards.Company OverviewMetricValueShare Price (as of market close 2026-08-04)$49.09Market Capitalization$73.0 billionRevenue (TTM)$21.0 billionNet Income (TTM)$3.7 billionCompany SnapshotBoston Scientific designs, manufactures, and commercializes a comprehensive portfolio of innovative medical devices across three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular, serving diverse interventional medical specialties globally.The company generates revenue through the development and sale of specialized medical devices and solutions that address clinical needs across gastrointestinal, cardiovascular, neuromodulation, and surgical intervention markets.Boston Scientific serves hospitals, healthcare systems, interventional specialists, and patients worldwide, positioning itself as a critical partner for healthcare providers seeking advanced treatment solutions across multiple therapeutic areas.Boston Scientific Corporation is a global leader in medical technology with a market capitalization of $73 billion and trailing twelve-month (TTM) revenue of $21 billion, employing 59,000 professionals across its operations. The company maintains a diversified business model spanning three strategic segments that collectively address a broad spectrum of clinical needs in interventional medicine. With a TTM net income of $3.7 billion, Boston Scientific demonstrates strong operational profitability and positions itself as a key innovator in the medical device sector, competing on the basis of technological advancement, clinical efficacy, and global market reach.
What this transaction means for investorsThere are many reasons an insider may sell shares in a company. One reason could be the need to raise cash to pay for a large personal expense. Another reason could be for reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company’s future.
However, there is only one reason an insider buys stock: they believe the share price is going up.
By this Wall Street rule of thumb, Mahoney’s purchase of more than $10 million of Boston Scientific shares is bullish. Adding to the bullishness is that studies show an insider purchase presages a higher share price 30 days later, more often than not.
The size of Mahoney’s purchase is significant, too. Hard data is tough to find , but very few insider purchase transactions in any one year are for more than $10 million, across the stock market, especially when you exclude investment funds and just focus on individuals.
Boston Scientific has been having a tough 2026, with management having twice cut revenue guidance due to a competitive marketplace. But the company’s future is looking brighter thanks to acquisitions that now mean the company has a robust pipeline of new products due to hit the market in 2027 through 2029. Mahoney is also leading a restructuring that promises to cut $500 million of fat from operations going into 2027.
An insider purchase of stock is no guarantee shares will go higher, but a sizable statement by a CEO like Mahoney is a signal that investors should take a close look at Boston Scientific shares.
David C. Habiger, a Director at Boston Scientific Corporation (BSX +2.48%), purchased 2,100 shares of Common Stock on August 5, 2026, according to an SEC Form 4 filing.
Today's Change
(
2.48
%) $
1.23
Current Price
$
50.54
Transaction summaryMetricValueShares purchased2,100Transaction value$99,939Post-transaction shares (directly held)17,160Post-transaction value$819,218.40Transaction value based on SEC Form 4 weighted average purchase price ($47.59); post-transaction value based on August 5, 2026 market close ($47.74).
Key questionsHow does this purchase align with current valuation and historical performance?
Habiger acquired the equity at a fraction of a penny less than $47.59 per share, a period during which the stock had declined 54% over the 12 months ending on the Aug. 5, 2026 transaction date.What is the scale of the insider's total ownership interest?
Following this transaction, Habiger maintains a direct ownership interest of 17,160 shares, representing about one one-thousandth of 1% of the $73.3 billion medical device company.What were the specific execution mechanics of this trade?
The director utilized a weighted average pricing structure for the transaction, with individual purchase prices ranging from $47.21 to $47.98 per share.How has the stock performed relative to this transaction price recently?
The stock was priced at $49.30 as of the Aug. 6, 2026 market close, which is approximately 3.59% above the weighted average price paid by the insider.Company OverviewMetricValueShare Price (as of market close 2026-08-06)$49.30Market Capitalization$73.3 billionRevenue (TTM)$21.0 billionNet Income (TTM)$3.7 billionCompany SnapshotBoston Scientific Corporation designs, manufactures, and commercializes a comprehensive portfolio of innovative medical devices across three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular, addressing diverse interventional medical specialties globally.The company generates revenue by developing and distributing specialized medical technology solutions that enable healthcare providers to deliver advanced therapeutic and diagnostic interventions across multiple clinical disciplines.Boston Scientific serves hospitals, healthcare systems, and interventional specialists worldwide, targeting patients requiring advanced medical device solutions across cardiology, gastroenterology, neurology, and surgical specialties.Boston Scientific Corporation is a global leader in medical technology with approximately 59,000 employees and a market capitalization of $73 billion. The company maintains a diversified product portfolio across three strategic business segments, positioning itself as a comprehensive provider of innovative medical devices for interventional procedures. With trailing twelve month (TTM) revenues of $21 billion and net income of $3.7 billion, Boston Scientific demonstrates significant scale and profitability within the medical device sector, supported by its commitment to advancing therapeutic solutions across multiple clinical specialties.
What this transaction means for investorsThere are multiple reasons a company insider may sell shares in the business. One reason could be the need to raise cash to meet a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company’s future.
However, there is only one reason an insider buys stock: they believe the share price is going up.
By that investor’s rule of thumb, Habiger’s purchase of $100,000 worth of Boston Scientific shares is bullish. Adding to the bullishness is the fact that studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.
At first glance, an investor may question why an insider like Habiger, best known as the vice chair of J.D. Power, would be bullish on Boston Scientific. The company has been having a tough 2026, with management cutting revenue guidance twice due to a competitive marketplace. But the company’s future looks brighter thanks to acquisitions that have created a robust pipeline of new products set to hit the market in 2027 through 2029. Management is also pushing a restructuring that promises to cut $500 million of fat from operations going into 2027.
Even a relatively small-scale purchase like Habiger is positive — no one likes to lose money. And since he has been a director since 2024, he surely knows enough about the business to feel good about its future.
An insider purchase of stock is no guarantee shares will go higher, but a buying statement by a director like Habiger is a signal that investors should take a close look at Boston Scientific shares.
, /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and global chief medical officer, will participate in a 35-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET.
Additionally, the company will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2026, on Wednesday, October 28, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter 2026 on October 28 prior to the conference call.
A live webcast and replay for each event will be accessible at https://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
[email protected]
Key Takeaways Boston Scientific cut 2026 sales and EPS guidance as WATCHMAN and EP weakness cloud visibility.Lower WATCHMAN and EP sales are expected to pressure product mix, margins and operating leverage.Key launches and restructuring benefits are delayed, pushing a broader recovery toward 2028. Boston Scientific Corporation (BSX - Free Report) lowered its 2026 sales and earnings outlook after slower WATCHMAN demand, U.S. electrophysiology share losses and limited operating leverage weakened near-term visibility.
The cut shifts the investment case from durable portfolio growth toward execution. Investors now must judge whether current pressure is a transition that clears by 2028 or the start of a longer stretch of slower growth and constrained margins.
BSX Cuts Growth and Earnings ExpectationsBoston Scientific now expects reported sales growth of 5.5-6.5%, below its prior 7-8.5% range. Organic sales growth guidance fell to 5-6% from 6.5-8%, while adjusted earnings expectations declined to $3.28-$3.32 per share from $3.34-$3.41.
The third-quarter outlook also points to a sharper slowdown. Management expects reported and organic sales growth of 3-5% and adjusted earnings of 80-82 cents per share. The Zacks Consensus Estimate for third-quarter earnings stands at 84 cents, leaving the company’s range below the consensus mark.
Image Source: Zacks Investment Research
Boston Scientific’s Product Mix Pressures MarginsLower WATCHMAN and electrophysiology sales are expected to weaken product mix and push full-year adjusted gross margin below the 2025 level. Boston Scientific also reduced expected adjusted operating margin expansion to 0-25 basis points from its prior 50-75 basis-point range.
Supply-chain and quality-system investments remain elevated, limiting the conversion of revenue growth into earnings leverage. This matters because the company is still expanding across much of its portfolio, yet weaker mix in high-value cardiovascular franchises may keep margin progress muted.
BSX Pushes Key Recovery Catalysts Into 2027Competitive gaps will not close quickly. FARAWAVE Ultra and intracardiac echocardiography products are expected in the second half of 2027, while the PRECEDENT defibrillator platform is also not expected until that period. Management does not anticipate an electrophysiology recovery before those launches.
That timing leaves Boston Scientific exposed while rivals continue to advance. Abbott Laboratories (ABT - Free Report) entered 2026 with new U.S. approvals in electrophysiology and later reaffirmed 6.5-7.5% comparable sales growth guidance. Zimmer Biomet Holdings, Inc. (ZBH - Free Report) , another medical-device peer, reported 2.9% organic constant-currency growth in the first quarter and updated its 2026 outlook.
Boston Scientific’s Restructuring Delays the PayoffThe restructuring program targets about $500 million in run-rate savings exiting 2029. More than half of the savings and related program spending are expected by the end of 2027, so the near-term period carries both implementation costs and only partial benefits.
Management expects revenue growth below its weighted average market growth rate and limited adjusted earnings growth in 2027. A broader recovery is therefore pushed toward 2028, when product launches, cost savings and a more stable mix may begin to work together.
Meanwhile, shares of Boston Scientific have gained 3.7% since the second-quarter earnings announcement, against the industry’s 1.5% decline. This is primarily attributable to the second-quarter earnings beat and continued growth across much of Boston Scientific’s portfolio despite the reduced outlook.
Image Source: Zacks Investment Research
Why BSX’s Current Signals Favor CautionThe bottom line is that Boston Scientific still has a broad franchise, international growth and pipeline depth, but its reduced outlook makes the path to recovery longer and less visible. WATCHMAN weakness, electrophysiology competition and delayed margin leverage now outweigh the near-term offsets.
BSX currently carries a Zacks Rank #5 (Strong Sell), which aligns with downward earnings estimate revisions and weaker visibility. Its Value Style Score of C, Growth Score of C, Momentum Score of C and VGM Score of C show no clear style-based strength to offset the unfavorable rank. The combination supports a balanced but cautious reading rather than a firm conclusion about the stock’s longer-term outcome.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
) manufactures medical devices and products used in various interventional medical specialties worldwide, including cardiovascular and surgical categories.On July 29, BSX reported revenue of $5.44 billion for their June quarter, up 7.5% over the same period last year. EPS came in at $0.86, compared to $0.75 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.38 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.
In response to the conference call and management's lowered guidance, analysts notched down their EPS estimates for this year and next, causing BSX shares to fall into the cellar of the Zacks Rank.
Since its 2025 highs near $110, BSX has been in a steady bear market, making new 52-week lows above $42 last month -- despite nearly doubling revenues in the last 5 years to cross $21 billion.
The stock may soon sort out a bottom after this report given other strong metrics under the hood of the business which continues to grow the top and bottom lines at mid-single digits.
Key Metrics Versus Estimates
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- Rest of the World: $2.02 billion compared to the $1.98 billion average estimate based on two analysts. The reported number represents a change of +9.8% year over year.
Geographic Revenue- U.S.: $3.43 billion versus $3.39 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
Net Sales- MedSurg- Worldwide: $1.82 billion compared to the $1.8 billion average estimate based on five analysts. The reported number represents a change of +5.9% year over year.
Net Sales- Cardiovascular- Worldwide: $3.62 billion versus $3.6 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change.
Net Sales- MedSurg- Neuromodulation- Worldwide: $341 million versus $335.33 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change.
Net Sales- MedSurg- Endoscopy- Worldwide: $793 million versus $774.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.
Net Sales- MedSurg- Urology- Worldwide: $684 million compared to the $694.74 million average estimate based on four analysts. The reported number represents a change of +1.2% year over year.
Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $585 million compared to the $601.79 million average estimate based on three analysts. The reported number represents a change of -0.9% year over year.
Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide: $1.33 billion compared to the $1.26 billion average estimate based on three analysts. The reported number represents a change of +82.4% year over year.
Net Sales- Cardiovascular- Watchman- Worldwide: $507 million compared to the $535.88 million average estimate based on three analysts. The reported number represents a change of +4.3% year over year.
Net Sales- Cardiovascular- Electrophysiology- Worldwide: $916 million versus $923.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
Key Takeaways Boston Scientific cut 2026 organic growth guidance to 5%-6% and lowered adjusted EPS guidance.WATCHMAN demand weakened, while U.S. electrophysiology share losses added near-term pressure.Debt rose to about $12.62 billion, and key recovery products are not expected before late 2027. Boston Scientific Corporation (BSX - Free Report) retains durable medical-device franchises, but its investment case has become harder to defend. Management lowered its 2026 outlook as WATCHMAN demand weakened, U.S. electrophysiology lost share and operating leverage fell short.
The stock’s valuation has compressed, creating potential upside if execution improves. Yet limited earnings visibility through 2027, higher debt and delayed product catalysts suggest investors may be better served by waiting for clearer signs of stabilization.
Why Boston Scientific’s Growth Outlook Has WeakenedBoston Scientific cut its 2026 organic sales growth guidance to 5%-6% from 6.5%-8%. Adjusted earnings guidance fell to $3.28-$3.32 per share from $3.34-$3.41, while third-quarter organic growth is expected at 3%-5%.
Here's where the consensus estimates for the company's 2026 earnings currently stand.
Image Source: Zacks Investment Research
The company now anticipates only 0-25 basis points of adjusted operating-margin expansion in 2026. Lower WATCHMAN and electrophysiology sales are hurting product mix, and elevated supply-chain and quality-system spending remains a drag. Management expects revenue growth below its weighted-average market rate and limited adjusted earnings growth in 2027.
BSX Faces Pressure in WATCHMAN and ElectrophysiologyU.S. WATCHMAN demand slowed as new clinical evidence disrupted patient identification and referral patterns. Standalone procedures declined at a low-teens rate in the second quarter, while management expects global WATCHMAN sales to fall at a mid- to high-single-digit rate in the second half of 2026.
Electrophysiology presents another near-term challenge. U.S. share losses exceeded expectations, and the existing FARAPULSE portfolio may not offset the pressure now that pulsed-field ablation represents about 80% of the U.S. atrial fibrillation market. Medtronic plc (MDT - Free Report) is expanding its Affera and PulseSelect pulsed-field ablation offerings, while Johnson & Johnson (JNJ - Free Report) is advancing its VARIPULSE platform, underscoring the competitive intensity confronting Boston Scientific’s FARAPULSE franchise.
Boston Scientific Still Has Durable Growth EnginesThe broader portfolio remains resilient. Second-quarter organic sales rose 12.2% in Neuromodulation and 7% in Endoscopy. International operations also provided support, with operational growth of 11.2% in Asia-Pacific and 16.2% in Latin America and Canada.
Interventional Cardiology, the FARAPULSE ecosystem, OPAL mapping, WATCHMAN FLX Pro and the wider pipeline could support longer-term growth. The Penumbra transaction and MiRus investment add vascular and structural-heart opportunities. Edwards Lifesciences Corporation (EW), whose transcatheter aortic valve replacement sales grew 11.3% in the second quarter of 2026, shows the scale of the structural-heart market Boston Scientific hopes to re-enter.
BSX Valuation Reflects Both Damage and UncertaintyBSX trades at 14.6X forward 12-month earnings, below its five-year median of 25.2X, the Medical-Products sub-industry’s 17.3X and the broader sector’s 20.6X. That discount could reward investors if growth and margins recover.
Image Source: Zacks Investment Research
The lower multiple also reflects material uncertainty. Earnings estimates have moved down, key recovery products are not expected until the second half of 2027 or later and execution remains critical. Cash fell to $539 million at the end of the second quarter, while total debt increased to about $12.62 billion.
Why BSX's Bearish Signals Still MatterThe balance of evidence favors patience rather than an aggressive purchase. Boston Scientific has valuable franchises and a credible pipeline, but weaker guidance, competitive gaps and delayed catalysts leave little room for execution errors.
BSX currently carries a Zacks Rank #5 (Strong Sell), indicating an unfavorable earnings-estimate revision trend over the next one to three months. Its Value Score of C, Growth Score of C, Momentum Score of C and VGM Score of C provide no strong style-based counterweight. The valuation is cheaper, but the near-term risk-reward profile still supports waiting for better visibility.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
First National Bank of Mount Dora Trust Investment Services purchased a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 134,736 shares of the medical equipment provider’s stock, valued at approximately $8,455,000. Boston Scientific makes up approximately 1.8% of First National Bank of Mount Dora Trust Investment Services’ portfolio, making the stock its 21st largest holding.
Other hedge funds have also bought and sold shares of the company. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific during the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific in the first quarter valued at approximately $28,000. Finally, Sfam LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $29,000. 89.07% of the stock is owned by institutional investors.
Analysts Set New Price Targets A number of equities research analysts recently issued reports on BSX shares. Mizuho reduced their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Oppenheimer cut their target price on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 27th. Evercore set a $65.00 price objective on shares of Boston Scientific in a research note on Monday, July 6th. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, Canaccord Genuity Group reduced their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $71.62.
Get Our Latest Stock Report on BSX
Trending Headlines about Boston Scientific Here are the key news stories impacting Boston Scientific this week:
Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations. Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring Boston Scientific Stock Up 0.0% Shares of NYSE:BSX opened at $46.75 on Monday. The company has a fifty day moving average of $46.13 and a 200-day moving average of $62.02. The company has a market capitalization of $69.48 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.
Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.
Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.
Insider Buying and Selling at Boston Scientific In other news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by insiders.
Boston Scientific Profile (Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Read More Five stocks we like better than Boston Scientific 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story AbbVie Quietly Solved Its Biggest Problem—Now What? Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFirst National Bank of Mount Dora Trust Investment Services Sells 2,298 Shares of S&P Global Inc. $SPGI
NEXT HEADLINE »First National Bank of Mount Dora Trust Investment Services Acquires New Position in Republic Services, Inc. $RSG
Bank of America Corp DE trimmed its position in Boston Scientific Corporation (NYSE:BSX – Free Report) by 9.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,756,646 shares of the medical equipment provider’s stock after selling 2,358,539 shares during the quarter. Bank of America Corp DE owned about 1.53% of Boston Scientific worth $1,427,980,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific during the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at about $26,000. Bangor Savings Bank grew its position in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific in the 1st quarter valued at approximately $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.
Trending Headlines about Boston Scientific Here are the key news stories impacting Boston Scientific this week:
Positive Sentiment: Second-quarter results exceeded expectations. Boston Scientific reported revenue of $5.442 billion, up 7.5% year over year, and adjusted earnings of $0.86 per share versus the $0.83 consensus estimate. Cardiovascular sales increased 8.3%, while international growth was particularly strong in APAC and LACA. Boston Scientific announces results for second quarter 2026 Positive Sentiment: Cost savings and product development may support longer-term growth. Boston Scientific is pursuing a multiyear restructuring program targeting approximately $500 million in annual savings, received FDA clearance for its TruSelect 2.6 Microcatheter and invested $1.5 billion in MiRus, including an option to acquire its TAVR business. The company also completed a $2 billion accelerated share repurchase. Positive Sentiment: Analysts remain broadly bullish despite lower targets. TD Cowen, Truist and BTIG retained “buy” ratings, while UBS reaffirmed its “buy” rating. However, their price targets were reduced to reflect more cautious near-term assumptions. What Are Wall Street Analysts’ Target Price for Boston Scientific Stock? Neutral Sentiment: Boston Scientific is acquiring Penumbra. Penumbra reported second-quarter revenue of $390.0 million, up 14.9%, with gross margin improving to 67.9%. The company will not provide full-year guidance or hold a conference call because of the pending acquisition by Boston Scientific. The deal could expand BSX’s thrombectomy and embolization portfolio, but integration and transaction costs remain factors for investors. Penumbra, Inc. Reports Second Quarter 2026 Financial Results Negative Sentiment: Lower guidance overshadowed the quarterly beat. Boston Scientific now expects full-year adjusted EPS of $3.28–$3.32, below the prior $3.34–$3.41 range and analyst expectations of roughly $3.36. Third-quarter EPS and revenue guidance also fell short of consensus. Negative Sentiment: WATCHMAN and electrophysiology headwinds are weighing on expectations. Softer WATCHMAN demand, competition and slower EP growth prompted management to temper its outlook. The company also faces a product recall and expects restructuring costs of approximately $700 million to $800 million through 2029. Boston Scientific trims annual profit forecast on softer Watchman device demand Boston Scientific Stock Performance Shares of NYSE:BSX opened at $45.92 on Friday. The stock has a market capitalization of $68.25 billion, a P/E ratio of 18.59, a P/E/G ratio of 0.89 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The business has a 50-day moving average price of $46.35 and a two-hundred day moving average price of $62.37.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the company earned $0.75 EPS. Boston Scientific’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.31 earnings per share for the current year.
Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.
Insider Transactions at Boston Scientific In related news, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.
Analysts Set New Price Targets A number of research analysts recently commented on the company. TD Cowen cut their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday. Bank of America lowered their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, July 25th. Finally, Robert W. Baird set a $56.00 price objective on Boston Scientific in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $71.62.
Read Our Latest Report on Boston Scientific
Boston Scientific Company Profile (Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Stories Five stocks we like better than Boston Scientific Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of America Corp DE Cuts Holdings in Mondelez International, Inc. $MDLZ
NEXT HEADLINE »Stifel Nicolaus Issues Positive Forecast for Microsoft (NASDAQ:MSFT) Stock Price
, /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Revenue of $390.0 million in the second quarter of 2026, an increase of 14.9% compared to the second quarter of 2025. Global thrombectomy revenue of $259.0 million in the second quarter of 2026, an increase of 12.5% compared to the second quarter of 2025. Global embolization and access revenue of $131.1 million in the second quarter of 2026, an increase of 20.0% compared to the second quarter of 2025. Gross profit margin of 67.9% in the second quarter of 2026, an increase of 1.9% compared to the second quarter of 2025. Total operating expenses of $223.9 million in the second quarter of 2026, comprised of R&D of $25.4 million and SG&A of $198.5 million, which includes $6.9 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation. Income from operations of $41.0 million and net income of $34.8 million in the second quarter of 2026. Full Year 2026 Financial Outlook and Webcast and Conference Call Information
Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended June 30, 2026.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)
June 30, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$ 205,271
$ 186,897
Marketable investments
453,524
357,919
Accounts receivable, net
190,407
190,021
Inventories
442,650
431,549
Prepaid expenses and other current assets
52,270
50,298
Total current assets
1,344,122
1,216,684
Property and equipment, net
146,718
117,436
Operating lease right-of-use assets
167,194
173,587
Finance lease right-of-use assets
24,357
25,972
Intangible assets, net
5,742
6,186
Goodwill
166,523
166,750
Deferred taxes
79,376
79,188
Other non-current assets
40,691
40,716
Total assets
$ 1,974,723
$ 1,826,519
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$ 44,728
$ 34,736
Accrued liabilities
172,270
132,163
Current operating lease liabilities
14,398
13,841
Current finance lease liabilities
2,380
2,393
Total current liabilities
233,776
183,133
Non-current operating lease liabilities
176,304
182,751
Non-current finance lease liabilities
19,628
20,714
Other non-current liabilities
14,249
12,318
Total liabilities
443,957
398,916
Stockholders' equity:
Common stock
39
39
Additional paid-in capital
1,224,278
1,185,525
Accumulated other comprehensive income
1,363
4,348
Retained earnings
305,086
237,691
Total stockholders' equity
1,530,766
1,427,603
Total liabilities and stockholders' equity
$ 1,974,723
$ 1,826,519
Penumbra, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenue
$ 390,046
$ 339,455
$ 764,804
$ 663,595
Cost of revenue
125,102
115,445
246,449
223,702
Gross profit
264,944
224,010
518,355
439,893
Operating expenses:
Research and development
25,396
23,218
47,778
45,295
Sales, general and administrative
198,509
159,964
391,304
313,420
Total operating expenses
223,905
183,182
439,082
358,715
Income from operations
41,039
40,828
79,273
81,178
Interest and other income, net
5,148
4,482
8,602
7,990
Income before income taxes
46,187
45,310
87,875
89,168
Provision for income taxes
11,376
40
20,480
4,675
Net income
$ 34,811
$ 45,270
$ 67,395
$ 84,493
Net income per share:
Basic
$ 0.88
$ 1.17
$ 1.71
$ 2.18
Diluted
$ 0.88
$ 1.15
$ 1.70
$ 2.15
Weighted average shares outstanding:
Basic
39,353,965
38,834,917
39,314,912
38,699,307
Diluted
39,572,059
39,245,953
39,572,347
39,214,027
Penumbra, Inc.
Reconciliation of Revenue Growth by Geographic Regions
(unaudited)
(in thousands, except for percentages)
Three Months Ended June 30,
Change
2026
2025
$
%
United States
$ 305,445
$ 260,818
$ 44,627
17.1 %
International
84,601
78,637
5,964
7.6 %
Total
$ 390,046
$ 339,455
$ 50,591
14.9 %
Six Months Ended June 30,
Change
2026
2025
$
%
United States
$ 601,832
$ 517,678
$ 84,154
16.3 %
International
162,972
145,917
17,055
11.7 %
Total
$ 764,804
$ 663,595
$ 101,209
15.3 %
Penumbra, Inc.
Reconciliation of Revenue Growth by Product Categories
(unaudited)
(in thousands, except for percentages)
Three Months Ended June 30,
Change
2026
2025
$
%
Thrombectomy
$ 258,981
$ 230,256
$ 28,725
12.5 %
Embolization and Access
131,065
109,199
21,866
20.0 %
Total
$ 390,046
$ 339,455
$ 50,591
14.9 %
Six Months Ended June 30,
Change
2026
2025
$
%
Thrombectomy
$ 512,898
$ 456,800
$ 56,098
12.3 %
Embolization and Access
251,906
206,795
45,111
21.8 %
Total
$ 764,804
$ 663,595
$ 101,209
15.3 %
Investor Relations
Penumbra, Inc.
[email protected]
Boston Scientific retains my buy rating with a $66 price target, reflecting 44% upside if negative earnings revisions stabilize. BSX has reset expectations, slashing guidance and acknowledging competitive pressures, particularly in WATCHMAN and electrophysiology segments. Valuation is now attractive at 13.7x forward earnings, with further upside contingent on management halting guidance cuts and delivering execution consistency.
Key Takeaways Boston Scientific reported Q2 revenues of $5.442B, up 7.5%, with adjusted EPS up 15%.BSX expects 2026 growth of 5%-6%, with WATCHMAN and EP pressures weighing on outlook.Boston Scientific targets $500M run-rate savings and cites seven major launches by 2028. Boston Scientific Corporation (BSX - Free Report) delivered a solid second quarter, but management highlighted a tougher path ahead as pressure in WATCHMAN and electrophysiology changed the company’s near-term outlook. Executives reduced full-year expectations while emphasizing cost actions and future product catalysts.
The call focused on market shifts, competitive dynamics and the steps Boston Scientific is taking to return to stronger growth beyond 2027. Management also addressed analyst concerns around WATCHMAN demand and EP share trends.
BSX Faces WATCHMAN and EP HeadwindsMichael Mahoney, chairman, president & CEO, said the updated outlook reflects pressure concentrated in WATCHMAN and electrophysiology, while the broader portfolio continues to perform. He noted that roughly 75% of revenues are growing around 6%.
Mahoney said WATCHMAN growth slowed due to changing referral patterns following new clinical evidence, while EP faced greater-than-expected competitive share movement in the U.S. market.
The company expects these dynamics to weigh on 2026 and create a challenging 2027 before improvement from new launches and investments.
Boston Scientific Updates Its OutlookBoston Scientific expects full-year 2026 organic revenue growth of 5% to 6% and adjusted EPS of $3.28 to $3.32. Third-quarter organic revenue growth is projected at 3% to 5%, with adjusted EPS of $0.80 to $0.82.
Jonathan Monson, executive VP & CFO, said the second-half outlook assumes flat EPS growth, a mid- to high-single-digit decline in global WATCHMAN sales and approximately 6% growth from the base business.
The company also expects full-year adjusted operating margin expansion of 0 to 25 basis points, reflecting pressure from product mix and investments in supply chain and quality systems.
BSX Highlights Core Business StrengthBSX reported second-quarter revenues of $5.44 billion, up 7.5% year over year, surpassing the Zacks Consensus Estimate of $5.38 billion. Adjusted EPS rose 15% to $0.86 and beat the consensus mark of $0.83.
Mahoney highlighted strength in Interventional Cardiology, Neuromodulation, Interventional Oncology and Vascular businesses. Interventional Cardiology grew 15%, supported by coronary therapies, drug-coated balloons, imaging and complex PCI.
Boston Scientific also reported strong regional performance, including operational growth of 6% in the United States and 11% in Asia-Pacific.
Boston Scientific Builds Future Growth PlatformsBoston Scientific emphasized upcoming growth opportunities tied to product launches and strategic investments. Management pointed to seven major launches expected to address more than $25 billion in total addressable markets in 2028.
The company highlighted opportunities including SEISMIQ intravascular lithotripsy, hypertension treatment, Penumbra integration, ICE imaging, FARAWAVE Ultra and potential MiRus TAVR expansion.
Mahoney said the company expects Interventional Cardiology and cardiovascular technologies broadly to become major growth drivers over the coming years.
BSX Advances Cost Reduction EffortsBSX announced a restructuring program designed to deliver approximately $500 million in run-rate savings exiting 2029. Management expects savings to come initially from SG&A and later from the cost of goods sold.
Monson said more than half of the savings are expected to be realized exiting 2027, supporting stronger margin expansion and EPS growth beginning in 2028.
The company completed its $2 billion accelerated share repurchase program and invested $1.5 billion in MiRus, including an option related to its TAVR business.
Boston Scientific Addresses Investor ConcernsA JPMorgan analyst asked whether the revised outlook reflected conservatism or current trends. Mahoney said the changes were primarily driven by WATCHMAN and EP conditions observed entering the second half.
Management told analysts that EP performance should improve with future launches, including FARAWAVE Ultra and ICE market entry, while WATCHMAN recovery depends on market conditions and education efforts.
BSX Maintains Long-Term FocusBSX management maintained confidence in long-term growth while acknowledging near-term challenges. Executives emphasized disciplined spending, continued investment in priority businesses and execution against 2026 guidance.
The company expects improvement in revenue and EPS trends in 2028 and beyond, supported by restructuring benefits and new product platforms.
BSX’s Zacks Rank and Style Score SignalsBoston Scientific has a Zacks Rank #4 (Sell), with a Value Score of B, Growth Score of C, Momentum Score of D and VGM Score of C.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Rank focuses on earnings estimate revisions, while Style Scores evaluate characteristics such as value, growth and momentum. These indicators are designed to complement the Zacks Rank when assessing stocks. The Zacks Rank can change as analysts update earnings estimates following quarterly results.
Why These Three Big Buybacks Are Sending Very Different Signals to InvestorsBoston Scientific NYSE: BSX reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competitive pressure in U.S. electrophysiology.
Chief Executive Officer Mike Mahoney said organic sales rose 7% in the second quarter, while adjusted earnings per share increased 15% to $0.86. The company had guided for 5% to 7% organic revenue growth and adjusted EPS of $0.82 to $0.84. Mahoney said the EPS outperformance was primarily driven by favorable tax results.
Get Boston Scientific alerts:
Why Boston Scientific's Big Dip Could Be a Bigger OpportunityBoston Scientific now expects full-year organic revenue growth of 5% to 6%, compared with its prior outlook, and adjusted EPS of $3.28 to $3.32, representing growth of 7% to 8%. For the third quarter, the company projected organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82.
WATCHMAN and EP Drive Outlook Reduction Mahoney said the revised outlook was concentrated in two businesses that had previously been major growth drivers: WATCHMAN and electrophysiology, or EP.
Beware the Death Cross: 3 Stocks Triggering This Spooky SignalWATCHMAN sales grew 4% in the second quarter, including 18% international growth and 3% growth in the U.S. The company estimated that roughly one-third of U.S. WATCHMAN procedures are now performed concomitantly with other procedures. Concomitant procedures rose more than 60% year over year and 11% sequentially from the first quarter, while standalone procedures, which comprise the remaining two-thirds of procedures, declined by the low teens from the prior year.
Mahoney attributed the slowdown in the left atrial appendage closure, or LAAC, market to recently published clinical evidence related to stroke risk in atrial fibrillation patients, which has affected referrals and patient identification. He also cited operational inefficiencies as hospitals and physicians adopt concomitant procedures.
The company now expects global WATCHMAN growth to be flat to low single digits for the full year, with a mid- to high-single-digit year-over-year decline in the second half. In the U.S., Boston Scientific expects third-quarter WATCHMAN sales to decline by the mid-single digits sequentially from the second quarter, leading to flat full-year growth.
Chief Medical Officer Dr. Ken Stein said the company has seen a decline in referrals for patients with what he described as “soft indications,” including patients who prefer not to take anticoagulants without a clearly defined medical reason for an alternative. Boston Scientific plans to expand physician education, invest in commercial coverage and direct-to-patient outreach, and continue developing clinical evidence and product enhancements.
Stein also pointed to the SIMPLAAFY trial, expected to read out in the second half of 2026, which could help simplify post-implant drug regimens if it meets its endpoints. The company continues to believe data from its CHAMPION trial support a potential FDA labeling update and reconsideration of the Centers for Medicare & Medicaid Services national coverage decision.
EP sales increased 9% in the quarter, including 3% growth in the U.S. and 23% growth internationally. Mahoney said the company has seen faster-than-expected adoption of pulsed field ablation, or PFA, with PFA accounting for an estimated 80% to 85% of the U.S. atrial fibrillation market. The rapid transition has limited Boston Scientific’s ability to offset competitive share pressure in the U.S.
Boston Scientific expects global EP growth to be flat in the second half of 2026. U.S. EP sales are projected to decline by the mid-single digits sequentially in the third quarter, resulting in full-year U.S. EP growth ranging from flat to low single digits. International EP growth is expected to be approximately 20% for the full year.
Growth in Interventional Cardiology, Neuromodulation Despite the pressure in WATCHMAN and EP, Mahoney said approximately 75% of Boston Scientific’s revenue base is expected to grow about 6% in the second half, consistent with historical performance.
Cardiovascular sales rose 8% in the second quarter, while interventional cardiology and vascular therapies grew 12%. Interventional cardiology grew 15%, supported by coronary therapies, drug-coated balloons, imaging and complex percutaneous coronary intervention procedures. Vascular therapies grew 8%, aided by Varithena adoption and the company’s drug-eluting portfolio.
Neuromodulation revenue rose 12%, with double-digit growth in both pain and brain therapies. Mahoney said Nalu, acquired by Boston Scientific, contributed for a full quarter and was performing well as integration continued.
Endoscopy sales increased 7%, with continued strength from the AXIOS platform. The company also received FDA clearance for RIVOS, a device intended to consolidate procedural exchanges during endoscopic ultrasound biliary drainage.
Interventional oncology and embolization grew 12%, supported by global demand for its technology portfolio. Boston Scientific cited published results from the PROACTIF study of TheraSphere for liver malignancies and said it received FDA clearance for the TRUSELECT microcatheter.
Other businesses were more mixed. Urology grew 1%, affected by slower-than-expected recovery in sacral neuromodulation and pressure in stone management. Cardiac rhythm management sales declined 2%, as the company cited competitive pressure and portfolio gaps. Boston Scientific expects CRM to be flat for the full year, with some second-half contribution from EluPro.
Restructuring and 2027-28 Product Catalysts Chief Financial Officer Jon Monson said second-quarter revenue totaled $5.44 billion, up 7.5% on a reported basis. Foreign exchange added about 50 basis points of growth. Adjusted operating margin was 28.4%, up 70 basis points from the prior year, while adjusted gross margin rose 80 basis points to 70.3%.
On a GAAP basis, operating margin was 21.6%, including an approximately $75 million charge related to certain product liability cases and about $80 million in refunds on previously paid IEEPA tariffs. Free cash flow was $1.29 billion in the quarter, and the company expects approximately $3.8 billion for the full year.
Boston Scientific also announced a companywide restructuring program targeting approximately $500 million in run-rate savings exiting 2029. Monson said more than half of the savings are expected to be realized exiting 2027, with savings initially appearing in selling, general and administrative expenses and later in cost of goods sold.
The company expects limited EPS growth and challenging operating-margin expansion in 2027, reflecting continued WATCHMAN and EP softness, as well as the initial impact of its planned Penumbra acquisition. The transaction is expected to close in the second half of 2026, subject to remaining regulatory clearances.
Management said it expects its growth profile to improve in the second half of 2027 and more meaningfully in 2028 as products and platforms including FARAWAVE Ultra, intracardiac echocardiography, FARAFLEX, renal denervation, intravascular lithotripsy and potentially the MiRus TAVR platform advance. Mahoney said Boston Scientific estimates its weighted average market growth rate at approximately 7% to 8%.
About Boston Scientific (NYSE:BSX)Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Boston Scientific Right Now?Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook.
The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus estimate, while revenue reached $5.442 billion, compared with analyst expectations of $5.37 billion.
Revenue increased 7.5% on a reported basis and 7.0% on an operational and organic basis compared with the prior-year period.
Boston Scientific reported GAAP net income attributable to common stockholders of $907 million, or $0.61 per share, compared with $797 million, or $0.53 per share, in the same period a year earlier.
Adjusted EPS rose to $0.86 from $0.75 in the second quarter of 2025.
"Our team delivered a solid quarter while continuing to navigate a dynamic environment," Boston Scientific CEO Mike Mahoney said in a statement.
"We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."
The company’s Cardiovascular segment recorded the strongest growth among its two major businesses, with sales increasing 8.3% on a reported basis and 7.8% on an operational and organic basis.
The MedSurg segment reported sales growth of 5.9% on a reported basis and 5.4% on an operational and organic basis.
By geography, US sales increased 6.2% on both a reported and operational basis. Sales in Europe, the Middle East and Africa rose 6.1% on a reported basis and 4.2% operationally, while Asia-Pacific revenue grew 11.2% on both measures. Latin America and Canada recorded the highest growth rate, with sales up 22.4% on a reported basis and 16.2% operationally.
During the quarter, Boston Scientific completed its previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
Shares of Boston Scientific were up 1.3% at about $47 post-earnings.
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook.
The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus estimate, while revenue reached $5.442 billion, compared with analyst expectations of $5.37 billion.
Revenue increased 7.5% on a reported basis and 7.0% on an operational and organic basis compared with the prior-year period.
Boston Scientific reported GAAP net income attributable to common stockholders of $907 million, or $0.61 per share, compared with $797 million, or $0.53 per share, in the same period a year earlier.
Adjusted EPS rose to $0.86 from $0.75 in the second quarter of 2025.
"Our team delivered a solid quarter while continuing to navigate a dynamic environment," Boston Scientific CEO Mike Mahoney said in a statement.
"We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."
The company’s Cardiovascular segment recorded the strongest growth among its two major businesses, with sales increasing 8.3% on a reported basis and 7.8% on an operational and organic basis.
The MedSurg segment reported sales growth of 5.9% on a reported basis and 5.4% on an operational and organic basis.
By geography, US sales increased 6.2% on both a reported and operational basis. Sales in Europe, the Middle East and Africa rose 6.1% on a reported basis and 4.2% operationally, while Asia-Pacific revenue grew 11.2% on both measures. Latin America and Canada recorded the highest growth rate, with sales up 22.4% on a reported basis and 16.2% operationally.
During the quarter, Boston Scientific completed its previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
Shares of Boston Scientific were up 1.3% at about $47 post-earnings.
Boston Scientific (BSX - Free Report) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.61%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.8 per share when it actually produced earnings of $0.8, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Boston Scientific, which belongs to the Zacks Medical - Products industry, posted revenues of $5.44 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.07%. This compares to year-ago revenues of $5.06 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Boston Scientific shares have lost about 51.7% since the beginning of the year versus the S&P 500's gain of 8.5%.
What's Next for Boston Scientific?While Boston Scientific has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Boston Scientific was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.84 on $5.38 billion in revenues for the coming quarter and $3.35 on $21.58 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, LeMaitre Vascular (LMAT - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 4.
This medical device maker is expected to post quarterly earnings of $0.81 per share in its upcoming report, which represents a year-over-year change of +35%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
LeMaitre Vascular's revenues are expected to be $71.76 million, up 11.7% from the year-ago quarter.
Key Takeaways BSX beat Q2 earnings and revenue estimates, with shares rising 3.4% in pre-market trading.Boston Scientific posted strong cardiovascular, APAC, LACA and Neuromodulation growth in Q2.BSX lowered its 2026 sales and adjusted earnings outlook despite strong quarterly results. Boston Scientific Corporation (BSX - Free Report) reported second-quarter 2026 adjusted earnings of 86 cents per share, up 14.7% year over year. The figure beat the Zacks Consensus Estimate by 3.61%.
Revenues rose 7.5% on a reported basis to $5.44 billion and surpassed the consensus estimate by 1.07%. Cardiovascular growth, double-digit gains in Asia-Pacific (“APAC”) and Latin America and Canada (“LACA”) and strong Neuromodulation sales supported the quarter.
Following the earnings announcement, shares of BSX rose 3.4% in pre-market trading today.
BSX’s Segmental Results Reflect Broad-Based GrowthCardiovascular revenues totaled $3.62 billion, increasing 8.3% on a reported basis and 7.8% on an operational and organic basis. The segment generated roughly two-thirds of Boston Scientific’s quarterly revenues and remained the primary growth contributor.
MedSurg revenues rose 5.9% to $1.82 billion, with operational and organic growth of 5.4%. Within the segment, Endoscopy sales increased 7.6% to $793 million, while Neuromodulation revenues climbed 12.7% to $341 million. Urology revenues advanced 1.1% to $684 million, marking the slowest growth among the company’s reported businesses.
BSX Posts Broad Regional Sales GainsU.S. revenues increased 6.2% to $3.43 billion. The domestic market remained Boston Scientific’s largest region, generating nearly 63% of consolidated sales.
APAC revenues rose 11.2% to $878 million, while LACA sales surged 22.4% to $206 million. LACA operational growth was 16.2%. Europe, Middle East and Africa (“EMEA”) revenues increased 6.1% to $932 million, although operational growth was lower at 4.2% due to currency effects.
Boston Scientific Expands Quarterly MarginsThe gross margin expanded approximately 306 basis points (bps) year over year to 70.7%. The cost of products sold declined 2.6% to $1.59 billion in the reported quarter.
Selling, general and administrative expenses rose 5.1% to $1.80 billion. Research and development expenses increased 5.3% to $554 million, while royalty expenses plunged 14.3% to $12 million. Adjusted operating margin expanded approximately 71 bps to 28.4%.
BSX Advances Its Cardiovascular PipelineBoston Scientific presented data from the FRACTURE trial of the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The study met its primary endpoints, demonstrating procedural success and high freedom from major adverse cardiac events at 30 days.
The AVANT GUARD study also met its safety and effectiveness endpoints. FARAPULSE pulsed field ablation demonstrated statistical superiority over anti-arrhythmic drugs in patients with persistent atrial fibrillation who had not received prior treatment for the condition.
Boston Scientific Adds New Growth InvestmentsThe company invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire its transcatheter aortic valve replacement business. MiRus is developing the investigational SIEGEL balloon-expandable TAVR system.
BSX also completed its previously announced $2 billion accelerated share repurchase program. The transaction resulted in the repurchase of approximately 40 million shares, reducing the company’s outstanding share base.
BSX’s Q3 and Full-Year GuidanceBoston Scientific now expects reported sales growth of 5.5-6.5%, down from its prior forecast of 7-8.5%. Organic sales growth is now projected at 5-6% compared with the earlier range of 6.5-8%. The Zacks Consensus Estimate is currently pegged at $21.59 billion, indicating a 7.6% rise from the 2025 figure.
The company also reduced its full-year adjusted earnings forecast to $3.28-$3.32 per share from the earlier $3.34-$3.41. The Zacks Consensus Estimate is currently pegged at $3.35.
For the third quarter, management forecasts reported and organic sales growth of 3-5%. Adjusted earnings are expected between 80 cents and 82 cents per share. The Zacks Consensus Estimate for third-quarter revenues and earnings is projected at $5.39 billion and 84 cents, respectively.
Our TakeBoston Scientific exited the second quarter of 2026 with both earnings and revenues beating estimates. Despite navigating a dynamic environment, the company remained focused on disciplined execution and prioritized investments in the highest-impact opportunities. The expansion of both gross and adjusted operating margins also bodes well. However, the lowered top- and bottom-line outlook for 2026 is discouraging.
During the quarter, Boston Scientific announced clinical trial results that were presented in late-breaking sessions at Heart Rhythm 2026. This includes the AVANT GUARD study of FARAPULSE Pulsed Field Ablation for the treatment of persistent atrial fibrillation in patients who had not previously been treated for their condition. The company also secured the FDA’s 510(k) clearance for the TruSelect 2.6 Microcatheter, expanding its embolization portfolio.
BSX’s Zacks Rank and Key PicksBoston Scientific currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Quest Diagnostics (DGX - Free Report) and Medpace (MEDP - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.
Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, exceeding the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.
DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.
Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.
MEDP has an historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.
Boston Scientific Corporation (NYSE:BSX) stock is trading lower after the company cut its fiscal 2026 outlook, citing pressures on the Watchman and EP markets.
Q2 Beats EstimatesThe medical technology giant reported revenues of $5.442 billion on Wednesday, better than the consensus estimate of $5.361 billion, beating the management guidance of $5.34 billion-$5.44 billion.
The medical devices maker reported adjusted earnings of 86 cents, beating the consensus of 83 cents and the management guidance of 82-84 cents.
“Our team delivered a solid quarter while continuing to navigate a dynamic environment,” said Mike Mahoney, chairman and CEO of Boston Scientific. “We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities…”
Boston Scientific Cuts Fiscal 2026 Sales And Earnings GuidanceBoston Scientific lowered its fiscal 2026 adjusted earnings guidance from $3.34-$3.41 per share to $3.28-$3.32 per share, compared to the consensus of $3.36.
The company also cut its 2026 sales guidance from $21.479 billion-$21.78 billion to $21.178 billion-$21.379 billion, compared to the consensus of $21.562 billion.
In an earnings conference call, the company said the guidance reduction was due to Watchman heart implant, where the U.S. market has slowed sharply and unexpectedly, primarily driven by compounding clinical evidence which has impacted referral patterns; and second, EP, where the company did not anticipate the degree of competitive share movement it is now seeing in the U.S. market.
The company said, “While we are sharpening our forecasting processes and taking action to address controllable headwinds, our underlying assumptions are that these dynamics continue in 2027, resulting in revenue growth below our WAMGR and limited adjusted EPS growth. We expect our revenue and EPS growth profile to improve meaningfully in 2028.”
The company expects net sales growth of approximately 3%-5% on a reported and organic basis in the third quarter of 2026, equivalent to sales of $5.217 billion-$5.318 billion, compared to the consensus of $5.358 billion.
The medtech giant expects adjusted earnings of 80-82 cents versus the consensus of 83 cents.
Restructuring Plan Targets Long-Term Cost SavingsEarlier this week, Boston Scientific initiated a restructuring plan.
The company, in an SEC filing, said the plan will generate $700 million to $800 million in total pre-tax charges, including $600 million to $700 million in future cash outlays.
Once fully implemented, the company expects the restructuring to reduce gross annual pre-tax expenses by about $500 million, with a significant portion of the savings earmarked for strategic growth investments.
BSX Stock Price Activity: Boston Scientific shares were down 6.17% at $43.22 at the time of publication Wednesday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
For the quarter ended June 2026, Boston Scientific (BSX - Free Report) reported revenue of $5.44 billion, up 7.5% over the same period last year. EPS came in at $0.86, compared to $0.75 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.38 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- Rest of the World: $2.02 billion compared to the $1.98 billion average estimate based on two analysts. The reported number represents a change of +9.8% year over year.Geographic Revenue- U.S.: $3.43 billion versus $3.39 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.Net Sales- MedSurg- Worldwide: $1.82 billion compared to the $1.8 billion average estimate based on five analysts. The reported number represents a change of +5.9% year over year.Net Sales- Cardiovascular- Worldwide: $3.62 billion versus $3.6 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change.Net Sales- MedSurg- Neuromodulation- Worldwide: $341 million versus $335.33 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change.Net Sales- MedSurg- Endoscopy- Worldwide: $793 million versus $774.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.Net Sales- MedSurg- Urology- Worldwide: $684 million compared to the $694.74 million average estimate based on four analysts. The reported number represents a change of +1.2% year over year.Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $585 million compared to the $601.79 million average estimate based on three analysts. The reported number represents a change of -0.9% year over year.Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide: $1.33 billion compared to the $1.26 billion average estimate based on three analysts. The reported number represents a change of +82.4% year over year.Net Sales- Cardiovascular- Watchman- Worldwide: $507 million compared to the $535.88 million average estimate based on three analysts. The reported number represents a change of +4.3% year over year.Net Sales- Cardiovascular- Electrophysiology- Worldwide: $916 million versus $923.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.Net sales- Interventional Oncology & Embolization- Worldwide: 283.00 2 versus the two-analyst average estimate of 274.38 2.View all Key Company Metrics for Boston Scientific here>>>
Shares of Boston Scientific have returned +7.9% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Boston Scientific Corp (BSX) released its 8-K filing on July 29, 2026, highlighting a solid quarter with net sales of $5.442 billion, a 7.5% increase compared t
